Aktien Sensor

AbbVie Inc. has revised its earnings guidance downward due to a $2.7 billion research and development charge and market access challenges, but its long-term pipeline and strategic partnerships remain promising for the biotechnology firm.

AbbVie Inc. is experiencing a surge in its share price due to expansion projects, favorable market conditions, and regulatory advancements, but faces looming patent cliffs and increasing competition in key markets.

AbbVie Inc. has announced a series of strategic initiatives to expand its therapeutic portfolio, improve operational efficiency, and navigate market-driven pricing strategies, positioning the company for sustained growth in the biopharmaceutical sec…

AbbVie Inc. has demonstrated resilience in the face of patent expirations and intensifying competition, with a strong market access strategy, pipeline diversification, and shareholder value preservation, positioning the company for sustained growth …

AbbVie Inc. has achieved significant strategic gains through the public reimbursement of its schizophrenia treatment VRAYLAR in Canada, but faces regulatory hurdles, including a recent legal defeat in Mississippi, that may impact its future growth a…

AbbVie’s stock price reached a record high after the company’s drug Rinvoq had its exclusivity extended to 2037, boosting the company’s long-term growth outlook.

AbbVie Inc. sees its stock rise 3% after securing a significant licensing deal with Glenmark Pharmaceuticals, while also expanding its portfolio in psychedelic medicine through various collaborations and investments.

AbbVie Inc. has announced a dividend increase, regulatory approval for its ovarian cancer treatment Elahere, and recognition as one of the best workplaces in Asia, among other developments that signal the company’s continued growth and innovation.

AbbVie continues to drive innovation and expansion in the pharmaceutical industry, with recent approvals and acquisitions solidifying its position as a leader in the market.

AbbVie has made a $1.2 billion deal to acquire a depression treatment from Gilgamesh Pharmaceuticals, marking its entry into the psychedelic-based depression drug market.